MODULEX-GROUP
10.5.2021 09:02:09 CEST | Business Wire | Press release
Modulex Group announces today that current CEO Ketil M. Staalesen moves into a majority ownership role. This move, a long time in the making, will set Modulex up to achieve Staalesen’s goal of DKK 1 Billion in revenue and a Group EBITDA of 10%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005057/en/
A native Norwegian, Ketil is a citizen of the world, having lived in several countries worldwide, including Denmark, Germany, Spain, UK, Mexico and the US. He completed his MBA at EBCM Barcelona/Munich.
“This week marks my 20th anniversary at Modulex. I grew up in this company professionally, and I can’t think of a more fitting week to move into a majority ownership position and take Modulex into a new era.”
Modulex, founded by the LEGO Group, has been a Denmark headquartered company since 1963. With offices and factories around the world, Modulex is a global leader in visual communication solutions. Their capabilities started in manufacturing and evolved into architectural signage, Design + Build solutions, global rebranding and recently launched a line up of green products in a continuing effort to offer sustainable solutions to clients.
“I feel a great responsibility to honour the Danish roots and the founder, Godtfred Kirk Christiansen’s vision for Modulex. The company has weathered significant change over the decades, and thanks to my incredible team and personal commitment from Peter Thorsen, our position is very strong. I have always felt incredible support from the team,” says Staalesen. Thorsen, a trusted mentor and business associate to Staalesen, will stay on a minority partner.
“The future of Modulex is in excellent hands,” says Peter Thorsen. “I have had the pleasure of working and mentoring Ketil for many years and see him develop into the leader Modulex needs. His vision, passion and his ability to bring an idea into action will bring Modulex to a new level.”
For more information, visit modulex.com or contact media@modulex.com .
About Modulex:
Founded in 1963 by the LEGO group, Modulex is a global leader in visual communication and brand implementation. Rooted in Danish design excellence and a modular signage concept, Modulex has evolved its offering with design, wayfinding, exterior custom solutions, and brand implementations on a local or global scale. In 2019 the ISO9001 certified factory in Denmark created a sustainable product line and had been awarded the Green Network diploma for nine straight years. The multi-national group has five factories globally. It has a presence in over 300 cities across 45 countries, giving them infinite reach and the ability to deliver on its promise of global vision, local reach, and one company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom